MUTYH rs3219489: Understanding This Genetic Variant
The rs3219489 variant is a genetic change located within the MUTYH gene, which encodes an enzyme essential for repairing DNA damage. This specific variant is studied for its potential role in influencing how cells respond to certain therapeutic agents, such as alkylating and platinum-based drugs.
What each genotype means
Common base excision repair
This is the most common genotype for this variant in many populations. It represents the baseline activity for the MUTYH enzyme in the context of this specific genetic marker. Research into how this genotype influences response to alkylating or platinum-based chemotherapy is limited, so please discuss any planned cancer treatments with your oncologist.
This is the most frequent genotype observed globally, though exact percentages vary significantly by ancestry.
Heterozygous variant carrier
You carry one copy of the variant allele, sometimes referred to as Q338H or Q324H in older literature. While some studies have investigated whether this variant influences DNA repair capacity or sensitivity to certain chemotherapy agents, the evidence remains limited and inconsistent. Please consult with your healthcare provider or pharmacist regarding how your genetic profile might relate to specific medication responses.
This genotype is relatively common, appearing in a significant portion of the population across various world regions.
Homozygous variant carrier
You carry two copies of the variant allele. Some research has explored whether this genotype affects the structural stability of the MUTYH enzyme and its role in repairing DNA damage caused by alkylating or platinum-based agents. Because the clinical significance of this variant is still being studied, you should discuss the implications of this result with your clinician or a genetic counselor.
This genotype is less common than the heterozygous state but is present in many populations worldwide.
What is the rs3219489 Variant?
The rs3219489 variant is a single nucleotide polymorphism (SNP) located in the MUTYH gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. Specifically, this variant is a missense mutation, meaning the change in the DNA code results in the substitution of one amino acid for another in the final protein product. In this case, the change is identified as Gln310His. This alteration occurs in a region of the protein responsible for structural zinc coordination, which is critical for the enzyme's stability and function. Because this variant changes the physical structure of the protein, researchers investigate whether it impairs the enzyme's ability to perform its normal biological tasks. Understanding such variants is a key focus of pharmacogenomics, the study of how an individual's genetic makeup influences their response to medications.
The Role of the MUTYH Gene
The MUTYH gene provides the instructions for creating an enzyme known as adenine DNA glycosylase. This enzyme is a vital component of the base excision repair (BER) pathway, which acts as a cellular quality control system. During DNA replication, errors can occur, such as the incorrect pairing of adenine with 8-oxoguanine, a common type of oxidative DNA damage. The MUTYH enzyme identifies these mismatches and initiates the repair process to prevent mutations from becoming permanent in the genome. When the MUTYH gene is functioning correctly, it helps maintain genomic stability and prevents the accumulation of harmful mutations. If the gene is significantly impaired, as seen in conditions like MUTYH-associated polyposis (MAP), the cell's ability to repair DNA is compromised, which can lead to an increased risk of developing certain cancers, particularly in the colon and rectum.
Research and Clinical Evidence
Research into rs3219489 is primarily focused on its potential impact on therapeutic cytotoxicity, particularly regarding alkylating and platinum-based chemotherapy agents. These drugs work by damaging the DNA of rapidly dividing cells, such as cancer cells. Because the MUTYH enzyme is involved in DNA repair, variations that alter its function might theoretically change how sensitive or resistant a cell is to these treatments. However, the current evidence regarding the clinical impact of rs3219489 is considered limited. While laboratory studies have explored the structural consequences of the Gln310His change, there is no broad clinical consensus on how this specific variant should guide medical decision-making. It is important to note that genetic associations are often complex and influenced by many other factors. Consequently, this information should not be used to predict individual treatment outcomes or to make medical decisions without consulting a qualified healthcare professional.
Population Frequency and Interpretation
The rs3219489 variant is relatively common, with a minor allele frequency typically reported between 0.15 and 0.25 across various global populations. This means that a significant portion of the general population carries at least one copy of the variant allele. Because it is found at such frequencies, it is considered a common genetic variation rather than a rare mutation. When interpreting this information, it is essential to distinguish between common variants and those that cause rare, high-penetrance genetic disorders. Most people who carry this variant do not have a clinical condition related to it. If you have received genetic testing results that include this variant, it is best to discuss the findings with a genetic counselor or your physician. They can help place the result in the context of your overall health history and clarify what, if anything, it means for your specific medical situation.
How common is this variant?
The rs3219489 variant is common, with a minor allele frequency ranging from approximately 0.15 to 0.25 across diverse world populations.
Frequently asked questions
Is rs3219489 a cause of cancer?
No, rs3219489 is a common genetic variant and is not considered a direct cause of cancer. While the MUTYH gene is linked to cancer risk when both copies are severely impaired, this specific variant is generally studied for its potential influence on drug response rather than as a primary driver of disease.
Should I change my medication based on this result?
You should never change your medication or dosage based on genetic test results without speaking to your doctor. Pharmacogenomic findings are complex, and a clinician must consider your entire medical history, other medications, and clinical guidelines before making any adjustments.
What does 'limited evidence' mean in this context?
Limited evidence means that while there are scientific studies exploring the variant, there is not enough robust, large-scale clinical data to definitively state how it affects patient outcomes. It suggests that more research is needed to understand the clinical significance of the variant.
Where can I find more information about my specific genetic report?
If you have a clinical genetic report, the best resource is the healthcare provider who ordered the test or a certified genetic counselor. They are trained to interpret complex genetic data and explain what it means for your personal health.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3219489?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29